Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-01-25
2011-01-25
Li, Bao (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C424S093100, C435S069100
Reexamination Certificate
active
07875450
ABSTRACT:
The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.
REFERENCES:
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5437951 (1995-08-01), Lowy et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5714374 (1998-02-01), Arnold et al.
patent: 5723287 (1998-03-01), Russell et al.
patent: 6719978 (2004-04-01), Schiller et al.
patent: 2003/0072753 (2003-04-01), Schiller et al.
patent: 2006/0210587 (2006-09-01), Schiller et al.
patent: 2007/0238684 (2007-10-01), Hallek et al.
patent: 684782 (1994-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 752886 (1998-01-01), None
patent: 1088075 (2001-04-01), None
patent: 97/38723 (1997-10-01), None
patent: WO 9929723 (1999-06-01), None
patent: WO 0032227 (2000-06-01), None
Neirknck et al. Nature, 1999, vol. 5, No. 10, pp. 1157-1163.
Smahel et al. The Journal of Gene Medicine, 2004, vol. 6, pp. 1092-1101.
Tegge et al. Peptides, 1998, Aug. 30-Sep. 4, 1998, pp. 540-541.
Schodel et al. Behring Institute Mitteilungen 1997, vol. 98, pp. 114-119.
Wang Vaccine 2009, vol. 27, pp. 7377-7384.
Adams, S.E. 1993 “Induction of humoral and cellular immunity by recombinant, particulate antigen presentation systems” Vaccine Research 2(3):163-172. (Abstract only).
Canadian Patent Office Communication dated Apr. 23, 2008, pursuant to Canadian Application No. 2,347,411.
Communication of the EPO relating to application No. 99929292.3, Apr. 25, 2005.
European Patent Office, Interlocutory Decision in Opposition Proceedings (Art. 101(3)(a) and 106(2) EPC), The Opposition Division—at oral proceedings dated Oct. 11, 2009, Dec. 14, 2009, 53pages.
Chackerian et al., “Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies”, The Journal of Clinical Investigation, Aug. 2001, 108(3), 415-423.
Girod et al., “Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2”, Nature Medicine, Sep. 1999, 5(9), 1052-1056.
Smith et al., “Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody”, Journal of Virology, Mar. 1993, 67(3), 1148-1158.
Communication of the EPO relating to application No. 99929292.3, Apr. 25, 2005.
Zinkernagel Declaration, Jul. 22, 2002.
Aichele, P., et al. (1994) Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.PNAS USA91:444-448/.
Albert, L.J., et al. (1999) Molecular Mimicry and Autoimmunity.N. Engl. J. Med. 341:2068-2074.
Alkhatib, G., et al. (1996) CC CKR5: A Rantes, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1.Science272:1955-1958.
Alkhatib, G., et al. (1997) CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants.J. Biol. Chem. 272:19771-19776.
Altin et al. Analytical Biochemistry 1995, vol. 224, pp. 382-389.
Atchinson, R.E., et al. (1996) Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines.Science274:1924-1926.
Bachmann, M.F., et al. (1993) The Influence of Antigen Organization on B Cell Responsiveness.Science262:1448-1451.
Bachmann, M.F., et al. (1996) The influence of virus structure on antibody responses and virus serotype formation.Immunol. Today17:553-558.
Bachmann, M.F., et al. (1997) Neutralizing Antiviral B Cell Responses.Annu. Rev. Immunol. 15:235-270.
Bachmann, M.F., et al. (1997) The Role of Antibody Concentration and Avidity in Antiviral Protection.Science276:2024-2027.
Backer et al. Micro. Mole. Biol. Rev. 1999, vol. 63, No. 4, pp. 862-922.
Baker, T.S., et al. (1991) Structures of bovine and human papillomaviruses Analysis by cryoelectron microscopy and three-dimensional image reconstruction.Biophys. J. 60:1445-1456.
Baselga, J., et al. (1996) Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients with HER2
eu-Overexpressing Metastatic Breast Cancer.J. Clin. Oncol. 14:737-744.
Bloom, J.W., et al. (1993) Epitope Mapping and Functional Analysis of Three Murine IgG1 Monoclonal Antibodies to Human Tumor Necrosis Factor-α.J. Immunol. 151:2707-2716.
Booy, F.P., et al. (1998) Two Antibodies that Neutralize Papillomavirus by Different Mechanisms Show Distinct Binding Patterns at 13 Å Resolution.J. Mol. Biol. 281:95-106.
Boring, L., et al. (1996) Molecular Cloning and Functional Expression of Murine JE (Monocyte Chemoattractant Protein 1) and Murine Macrophage Inflammatory Protein 1α Receptors.J. Biol. Chem. 271:7551-7558.
Chackerian, B. et al. (2004) “Induction of autoantibodies to ccr5 in macaques and subsequent effects upon challenge with an r5-tropic simian/human immunodeficiency virus”Journal of Virology78:4037-4047.
Chackerian, B., et al. (1999) Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.PNAS USA96:2373-2378.
Chackerian, B., et al. (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.J. Clin. Invest. 108:415-423.
Chang, C. et al. (1994) “Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to becispreferential.”Journal of Virology, 68:5225-5231.
Chang, T.W. (2000) The pharmacological basis of anti-IgE therapy.Nat. Biotechnol. 18:157-162.
Choe, H., et al. (1996) The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates.Cell85:1135-1148.
Chu, R.S., et al. (1997) CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity.J. Exp. Med. 186:1623-1631.
Ciapponi, L., et al. (1997) Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist.Nat. Biotechnol. 13:997-1001.
Conry, R. M., et al. (Mar. 1995) Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man.Proceedings of the American Association for Cancer Research. 36:492 (Abstract 2930).
Dalum, I., et al. (1996) Breaking of B Cell Tolerance Toward a Highly Conserved Self ProteinJ. Immunol. 157:4796-4804.
Dalum, I., et al. (1997) Induction of Cross-reactive Antibodies Against a Self Protein by Immunization with a Modified Self Protein Containing a Foreign T Helper Epitope.Mol. Immunol. 34:1113-1120.
Dalum, I., et al. (1999) Therapeutic antibodies elicited by immunization against TNF-αNat. Biotechnol. 17:666-669.
Deng, H., et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1.Nature381:661-666.
Doranz, B.J., et al. (1996) A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors.Cell85:1149-1158.
Dragic, T., et al. (1996) HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5.Nature381:667-673.
Eck, M.J., et al. (1989) The Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution. J. Biol. Chem. 264:17595-17605.
Eigler, A., et al. (1997) Taming TNF: strategies to restrain this proinflammatory cytokine.Immunol. Today18:487-492.
Fehr, T., et al. (1997) Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies.J. Exp. Med. 185:1785-1792.
Fitchen, J., et al. (1995) Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response.Vaccine13:1051-1057.
Green, N.M. (1965) A Spectrophotmetric Assay for Avidin and Biotin Based on Binding of Dyes byAvidin. Biochem. J. 94:23c-24c.
Greenstone, H.L., et al. (1998) Chim
Chackerian Bryce
Lowy Douglas R.
Schiller John T.
Li Bao
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Virus-like particles for the induction of autoantibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus-like particles for the induction of autoantibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus-like particles for the induction of autoantibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679488